421 related articles for article (PubMed ID: 14521491)
1. Current pharmacotherapy for the treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Expert Opin Pharmacother; 2003 Oct; 4(10):1821-7. PubMed ID: 14521491
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Curr Pharm Des; 2002; 8(11):953-8. PubMed ID: 11945141
[TBL] [Abstract][Full Text] [Related]
4. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
5. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
6. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
7. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
8. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Ayres A; Bartholomeusz A; Lau G; Lam KC; Lee JY; Locarnini S
J Clin Virol; 2003 May; 27(1):111-6. PubMed ID: 12727536
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside analogues in the treatment of chronic hepatitis B.
Leung N
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E53-60. PubMed ID: 10921383
[TBL] [Abstract][Full Text] [Related]
11. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
12. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of pre-core mutant chronic hepatitis B.
Papatheodoridis GV; Hadziyannis SJ
J Viral Hepat; 2001 Sep; 8(5):311-21. PubMed ID: 11555188
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
15. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
[TBL] [Abstract][Full Text] [Related]
16. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
[TBL] [Abstract][Full Text] [Related]
17. Management of viral hepatitis B.
Pramoolsinsup C
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
[TBL] [Abstract][Full Text] [Related]
18. How will we use the new antiviral agents for hepatitis B?
Perrillo RP
Curr Gastroenterol Rep; 2002 Feb; 4(1):63-71. PubMed ID: 11825543
[TBL] [Abstract][Full Text] [Related]
19. Adefovir dipivoxil in chronic hepatitis B infection.
Yuen MF; Lai CL
Expert Opin Pharmacother; 2004 Nov; 5(11):2361-7. PubMed ID: 15500383
[TBL] [Abstract][Full Text] [Related]
20. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
